Tag: pharmaceuticals
-
Math Model Gauges Potential Tylenol Overdose, Liver Damage
Researchers at University of Utah and Baylor College of Medicine have devised a set of calculus equations to quickly estimate the amount of Tylenol ingested by a patient, and if the patient may need a liver transplant. Their work is scheduled to appear in an upcoming issue of the journal Hepatology. Acetaminophen is the generic…
-
Biotech, GSK to Partner on Rare Inherited Cellular Diseases
Angiochem, a biotechnology company in Montreal, Canada says it will collaborate with the global pharmaceutical company GlaxoSmithKline on treatments for lysosomal storage diseases, a type of rare, inherited conditions causing cellular dysfunctions. Under the agreement, Angiochem will be eligible for at least $300 million in payments. Lysosomal storage diseases are a class of disorders caused…
-
Patent Awarded for Migraine Drug Inhalation Method
MAP Pharmaceuticals Inc. in Mountain View, California says it received a U.S. patent for its formulation and method of administering the drug dihydroergotamine (DHE) used to treat migraine headaches. Patent 8,119,639 from the U.S. Patent and Trademark Office was awarded to four inventors including Thomas Armer, MAP Pharmaceuticals’s chief scientific officer. DHE is a type…
-
Pharmacist/Tech Initiative Found to Cut Medication Errors
An initiative led by pharmacists, using information technology was found to reduce more prescription errors by general practitioners than simple automated feedback among patients at risk for these errors. The findings by a team led by University of Nottingham medical professor Tony Avery, himself a practicing G.P. , appear online in the journal The Lancet…
-
J&J, University to Partner on Spider Venom Therapy for Pain
Researchers at University of Queensland in Australia are collaborating with the U.S. pharmaceutical company Johnson & Johnson to develop components of spider venom as a potential treatment for pain. Johnson & Johnson’s Corporate Office of Science and Technology (COSAT) and other company units will provide funding to the university’s Institute for Molecular Bioscience for the…
-
Device Company, MIT Test Drug-Delivery Implanted Microchip
Scientists at medical technology developer MicroCHIPS in Walthan, Massachusetts and MIT reported the results of a successful human clinical trial of a programmable and wirelessly controlled implanted microchip to deliver drugs. The results appear online in the journal Science Translational Medicine (paid subscription required). The trial, the first successful test of this type of device,…
-
Software to Aid Genome Analysis for Cancer Therapies
Researchers at Georgia Institute of Technology in Atlanta have developed software that analyzes ribonucleic acid (RNA) in the human genome to provide more useful data for generating personalized cancer therapies. The work of biology professor John McDonald (pictured left) and bioinformatics Ph.D. candidate Vinay Mittal is described and appears online in the journal Nucleic Acids…
-
FDA Approves Drug for Glaucoma, Ocular Hypertension
The pharmaceutical company Merck in Whitehouse Station, New Jersey says the Food and Drug Administration has approved its drug Zioptan to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Zioptan is the brand name for Merck’s tafluprost ophthalmic solution to reduce pressure inside the eye. Glaucoma is the second most common…
-
Pharma Companies to Partner on Cough and Cold Drugs
Vernalis plc in Winnersh, U.K. and Tris Pharma Inc. in Monmouth Junction, New Jersey have agreed to develop and market prescription cough and cold drugs in the U.S. Financial terms and timetable of the deal were not disclosed. Under the agreement, Tris will use its drug delivery technology to develop, on behalf of Vernalis, up…
-
FDA Releases Draft Biosimilars Guidance
The Food and Drug Administration has issued three guidance documents in draft on biosimilar therapeutics — functional equivalents of biologic therapies — that the agency says will soon be open for public comment. Guidance documents offer insights into the current thinking of FDA on key scientific and regulatory topics, and are not binding on the…